Equity grants and tax-related sale by Cryoport (CYRX) officer Zecchini

Rhea-AI Filing Summary

Cryoport, Inc. officer Edward J. Zecchini reported routine equity compensation activity and a small share sale. He received 21,322 shares of Common Stock as restricted stock rights that vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 63,965 shares at an exercise price of $8.60 per share expiring in 2033. On March 16, 2026, he sold 2,014 shares of Common Stock at $8.00 per share, with a footnote explaining the shares were required to be sold to pay taxes due on the vesting of restricted stock rights. After these transactions, he directly holds 109,719 shares of Common Stock.

Insider Trade Summary

Net Seller: 2,014 shares ($16,112)

Net Sell 3 txns

Insider ZECCHINI EDWARD J

Role See Remarks

Sold 2,014 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,014	$8.00	$16K
Grant/Award	Stock Option (right to buy)	63,965	$0.00	--
Grant/Award	Common Stock	21,322	$0.00	--

Holdings After Transaction: Common Stock — 109,719 shares (Direct); Stock Option (right to buy) — 63,965 shares (Direct)

Footnotes (1)

1. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZECCHINI EDWARD J

(Last) (First) (Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/14/2026		A		21,322	A	$0(1)	111,733	D
Common Stock	03/16/2026		S(2)		2,014	D	$8	109,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.6	03/14/2026		A		63,965		(3)	03/14/2033	Common Stock	63,965	$0	63,965	D

Explanation of Responses:

1. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.

2. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

3. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.

Remarks:

Chief Digital and Technology Officer

	/s/ Edward J. Zecchini	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Cryoport (CYRX) officer Edward J. Zecchini report?

He reported a grant of 21,322 restricted stock rights, a grant of 63,965 stock options, and the sale of 2,014 Common Stock shares. These transactions reflect routine equity compensation and a small tax-related share sale.

How many Cryoport (CYRX) shares does Edward J. Zecchini hold after these Form 4 transactions?

After the reported transactions, he directly holds 109,719 shares of Cryoport Common Stock. This figure reflects his position following the 2,014-share sale and the award of 21,322 restricted stock rights.

What are the terms of Edward J. Zecchini’s new Cryoport (CYRX) stock option grant?

He received stock options for 63,965 shares of Cryoport Common Stock at an exercise price of $8.60 per share, expiring in 2033. One forty-eighth vests monthly on the 14th, beginning April 14, 2026.

How do Edward J. Zecchini’s restricted stock rights in Cryoport (CYRX) vest?

The Form 4 states that 21,322 restricted stock rights vest in four equal annual installments beginning March 14, 2027. Each restricted stock right is a contingent right to receive one share of Cryoport Common Stock upon vesting.

Why did Edward J. Zecchini sell 2,014 Cryoport (CYRX) shares?

A footnote explains the 2,014 shares were required to be sold under company policies to pay taxes due upon vesting of restricted stock rights. This indicates a tax-related disposition rather than a discretionary open-market sale.

Is Edward J. Zecchini’s Form 4 activity in Cryoport (CYRX) mainly compensation-related?

Yes. The filing shows grants of restricted stock rights and stock options as compensation, plus a small sale of 2,014 shares to cover tax obligations on vesting, indicating routine, compensation-driven equity activity.